The US Food and Drug Administration cleared a number of molecular tests and immunoassays, as well as a clinical chemistry and a cellular deformation test.

Arrangements provide increased near-term funding and extend maturity of credit agreement to early 2027 - Equity settlement mechanisms also agreed for milestone payments and contingent acquisition ...